GO
Loading...

Express Scripts Holding Co

More

  • Final Glance: Drug Benefits companies Wednesday, 14 Jan 2015 | 6:07 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVSCaremark rose$. 09 or. 1 percent, to $97.33. Express Scripts Holding Co. rose$. 68 or. 8 percent, to $84.26.

  • Midday Glance: Drug Benefits companies Wednesday, 14 Jan 2015 | 1:43 PM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 1 p.m.:. CVSCaremark fell$. 64 or. 7 percent, to $96.60. Express Scripts Holding Co. rose$. 29 or. 3 percent, to $83.87.

  • Early Glance: Drug Benefits companies Wednesday, 14 Jan 2015 | 10:41 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVSCaremark fell$. 68 or. 7 percent, to $96.56. Express Scripts Holding Co. fell$. 21 or. 3 percent, to $83.37.

  • Final Glance: Drug Benefits companies Tuesday, 13 Jan 2015 | 6:15 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVSCaremark rose$. 04 or percent, to $97.24. Express Scripts Holding Co. rose$. 50 or. 6 percent, to $83.58.

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Midday Glance: Drug Benefits companies Tuesday, 13 Jan 2015 | 1:17 PM ET

    NEW YORK— Shares of some top drug benefits companies are up at 1 p.m.:. CVSCaremark rose$. 85 or. 9 percent, to $98.05. Express Scripts Holding Co. rose $1.38 or 1.7 percent, to $84.46.

  • Early Glance: Drug Benefits companies Tuesday, 13 Jan 2015 | 10:42 AM ET

    NEW YORK— Shares of some top drug benefits companies are up at 10 a.m.:. CVSCaremark rose $1.59 or 1.6 percent, to $98.79. Express Scripts Holding Co. rose $1.35 or 1.6 percent, to $84.43.

  • Final Glance: Drug Benefits companies Monday, 12 Jan 2015 | 6:36 PM ET

    NEW YORK— Shares of some top drug benefits companies were down at the close of trading:. CVSCaremark fell$. 72 or. 7 percent, to $97.20. Express Scripts Holding Co. fell $1.82 or 2.1 percent, to $83.08.

  • Midday Glance: Drug Benefits companies Monday, 12 Jan 2015 | 1:23 PM ET

    NEW YORK— Shares of some top drug benefits companies are down at 1 p.m.:. CVSCaremark fell$. 82 or. 8 percent, to $97.10. Express Scripts Holding Co. fell $1.63 or 1.9 percent, to $83.27.

  • Early Glance: Drug Benefits companies Monday, 12 Jan 2015 | 10:45 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVSCaremark fell$. 46 or. 5 percent, to $97.46. Express Scripts Holding Co. fell$. 98 or 1.2 percent, to $83.92.

  • Jan 8- Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the...

  • Jan 8- AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. U.S. health regulators approved Viekira Pak, AbbVie's all-oral treatment for hepatitis C in December. AbbVie's newly approved regimen is also cheaper than Gilead's...

  • Jan 5- CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception. The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows...

  • FDA approves 41 novel medicines in 2014 vs 27 in 2013. LONDON, Jan 1- U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines in...

  • It was a year when Cynk Technology, a development-stage company with no revenue, was briefly worth $6 billion, and when a long-forgotten closed-end fund focused on Cuba- the Herzfeld Caribbean Basin Fund- saw more trading in one day in December than it had in six years. With a current market value of about $663 billion, if one were to pick a company that would be the...

  • After-hours buzz: Cal-Maine Foods, Gilead & Sony Tuesday, 23 Dec 2014 | 5:00 PM ET

    Check out which companies are making headlines after the bell Tuesday: Cal-Maine Foods, Gilead & Sony.

  • *Dow, S&P rise for 5th day, both end at records. NEW YORK, Dec 23- U.S. stocks rose on Tuesday, with the Dow closing above 18,000 for the first time ever and the S&P 500 ending at a record after an unexpectedly strong report on economic growth. The Dow rose as high as 18,069.22 and is up about 175 percent from a 12- year closing low hit on March 9, 2009.

  • Record-setting day: Dow's first finish above 18,000 Tuesday, 23 Dec 2014 | 4:06 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Stocks furthered record gains Tuesday after the economy expanding in the third quarter by the most in 11 years.

  • NEW YORK, Dec 23- U.S. stocks rose for a fifth straight session on Tuesday, with the Dow climbing above 18,000 for the first time ever after an unexpectedly strong report on economic growth. Both the Dow and S&P 500 hit intraday records, and the S&P is on track for its 51st record close of 2014. The gains pushed the Dow as high as 18,051.14, and the blue-chip index is now up...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...